NeOnc Technologies Holdings, Inc Common Stock

Yahoo Finance • 5 months ago

NeOnc Technologies (Nasdaq: NTHI) Announces AI-Driven Findings Showing Ultrasound Enhances the Potency of an Already Effective NEO100 in Treating Primary and Metastatic Brain Tumors

CALABASAS, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI), a clinical-stage biopharmaceutical company developing brain-penetrant therapeutics for central nervous system (CNS) cancers, today ann... Full story

Yahoo Finance • 6 months ago

NeOnc Technologies Holdings Reports Third Quarter 2025 Results and Provides Operational Update

CALABASAS, Calif., Nov. 14, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (CNS) canc... Full story

Yahoo Finance • 6 months ago

NeOnc Technologies (Nasdaq: NTHI) to Host Investor Conference Call to Present Data Updates from Ongoing NEO100-1 Phase 1/2a Clinical Trial and Compassionate Use Program

CALABASAS, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- NeOncTechnologies Holdings, Inc. (NTHI) (“NeOnc” or the “Company”), a clinical-stage biopharmaceutical company developing novel brain-penetrant therapeutics for patients with malignant... Full story

Yahoo Finance • 7 months ago

NeOnc Technologies' Subsidiary, NuroMENA, Signs Master Services Agreement with M42’s IROS and Expands Board of Directors

CALABASAS, Calif. and ABU DHABI, United Arab Emirates, Oct. 09, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies f... Full story

Yahoo Finance • 7 months ago

NeOnc Technologies Appoints Dr. David M. Ashley, Director of The Preston Robert Tisch Brain Tumor Center at Duke, to Scientific Advisory Board

NeOnc Technologies Holdings, Inc.image1.jpeg CALABASAS, Calif., Oct. 02, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering the... Full story

Yahoo Finance • 7 months ago

NeOnc Technologies Appoints Renowned Neuro-Oncologist Dr. Henry S. Friedman to Scientific Advisory Board

CALABASAS, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (CNS) can... Full story

Yahoo Finance • 8 months ago

Blue Gold Appoints Quazar’s Sameer Salgar to Advisory Board to Establish UAE Ties and Guide Digital Gold Strategy

NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Blue Gold Limited (Nasdaq: BGL) ("Blue Gold" or the “Company”), a next-generation gold development and technology company, today announced the appointment of Sameer Salgar, Founding Partner an... Full story

Yahoo Finance • 8 months ago

NeOnc Technologies Receives FDA Authorization to Proceed with Phase II Clinical Trial of NEO212 – A First-in-Class Oral Chemical Conjugated Chemotherapy Candidate for Brain Cancer

CALABASAS, Calif., Sept. 10, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (... Full story

Yahoo Finance • 8 months ago

NeOnc Technologies Closes Strategic Acquisition of Advanced AI and 3D Bioprinting IP, Appointing World-Renowned Scientist Dr. Ishwar K. Puri to its Board

CALABASAS, Calif., Aug. 25, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI), a multi-Phase 2 clinical-stage biotechnology company pioneering therapies for central nervous system (CNS) cancers, today announced the... Full story

Yahoo Finance • 8 months ago

NeOnc Technologies Holdings GAAP EPS of $0.30

* NeOnc Technologies Holdings press release [https://seekingalpha.com/pr/20205072-neonc-technologies-holdings-reports-second-quarter-2025-results-and-provides-operational] (NASDAQ:NTHI [https://seekingalpha.com/symbol/NTHI]): Q2 GAAP EPS... Full story

Yahoo Finance • 8 months ago

NeOnc Technologies to restate first quarter 2025 financials due to RSU expense error

NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI), a small-cap biotech company with a market capitalization of $97.42 million, announced Monday that its unaudited consolidated financial statements for the quarter ended March 31, 2025, should... Full story

Yahoo Finance • 9 months ago

NeOnc secures $50 million investment following UAE subsidiary formation

ABU DHABI - NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI), currently valued at $91.14 million, announced Monday that its subsidiary NuroMENA Holdings Ltd. has been officially incorporated by the Abu Dhabi Global Market (ADGM), fulfilling... Full story

Yahoo Finance • 9 months ago

NeOnc Technologies Awarded $2.5 Million in NIH STTR Grants to Advance NEO212 in Gliomas and Leukemia

CALABASAS, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a multi–Phase 2 clinical-stage biotechnology company focused on breakthrough therapies for central nervous system (CNS) malignancies,... Full story

Yahoo Finance • 10 months ago

NeOnc Technologies Signs $50 Million Non-Binding Strategic Term Sheet with Quazar Investment to Launch GCC & MENA Expansion and Clinical Trials Platform

CALABASAS, Calif., July 08, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a clinical-stage biotechnology company advancing transformative treatments for brain and central nervous system cancers, today announc... Full story

Yahoo Finance • 11 months ago

NeOnc Technologies files to sell 10.02M shares of common stock by selling shareholders

* NeOnc Technologies (NASDAQ:NTHI [https://seekingalpha.com/symbol/NTHI]) filed a prospectus to resale 10.02M shares of common stock. * The company will not receive any proceeds from the sale of ordinary shares by the selling sharehold... Full story

Yahoo Finance • 11 months ago

NeOnc Technologies Holdings, Inc. Appoints Dr. Josh Neman as Chief Clinical Officer to Advance Clinical Strategy and Translational Oncology Programs

USC brain tumor authority to accelerate four clinical trials including lead asset NEO100 nearing Phase 2a completion ahead of schedule Appointment bolsters FDA approval path while company explores AI and quantum computing to enhance drug... Full story